Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus
Authors:
- Estela WajcbergEWEstela Wajcberg
- Ashdin TavariaATAshdin Tavaria
- 16 December 2008
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 10 (1) , 135-142
Abstract
Background: Exenatide is the first-in-class incretin mimetic for the treatment of type 2 diabetes. Objective: To assess exenatide's mechanism of action, therapeutic and adverse effects. Methods: Pharmacokinetics and pharmacodynamics of exenatide were reviewed, as well Phase I, II and III clinical trials, and postmarket reports. Results/conclusion: Exenatide improves fasting plasma glucose and HbA1c in type 2 diabetic patients not controlled on other antidiabetic drugs, due to its effects on glucose-dependent stimulation on insulin secretion, suppression elevated glucagon secretion, slowing the accelerated rate of gastric emptying, reduction of food intake and possible β-cell preservation. Nausea and vomiting were the most common and dose-related side effects. Rare reports of acute pancreatitis do not appear greater than the rate in the general population of patients with type 2 diabetes.Keywords
This publication has 34 references indexed in Scilit:
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetesAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 DiabetesDiabetes Care, 2007
- Clinical Observations of Exenatide TreatmentDiabetes Care, 2006
- Exendin-4 Pharmacodynamics: Insights from the Hyperglycemic Clamp TechniqueThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humansAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Rapid Gastric Emptying of a Solid Pancake Meal in Type II Diabetic PatientsDiabetes Care, 1996
- lnsulinotropic action of truncated glucagon‐like peptide‐1 in miceActa Physiologica Scandinavica, 1995